UK – Guidance on minimising disruptions to the conduct and integrity of clinical trials of medicines during COVID-19

Actions that trial sponsors should consider to build resilience into clinical trial design

This guidance follows on from that published on managing clinical trials during coronavirus (COVID-19) and has been developed to assist those involved in running clinical trials of medicines. This will avoid disruptions as a result of the continuing pandemic and will support appropriate incorporation of the available flexibilities into normal practice for the benefit of trial participants. It is relevant to those involved with ongoing studies, those wishing to restart trials that have been paused or temporarily halted, and those wishing to start new studies…